A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- Thailand, Philippines sign for AstraZeneca COVID-19 vaccineon November 28, 2020 at 12:06 pm
Thailand on Friday signed a $200 million deal to procure 26 million doses of a trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca in collaboration with Oxford University. It is ...
- Trump Distorts Military Role in Vaccineson November 28, 2020 at 12:06 pm
From the get-go, President Donald Trump has miscast or exaggerated the military's role in his administration's crash program to accelerate the development, production and eventual distribution of ...
- AP FACT CHECK: Trump Distorts Military Role in Vaccineson November 28, 2020 at 11:41 am
From the get-go, President Donald Trump has suggested that the military would be central in developing, producing and distributing vaccines for the pandemic ...
- PM Modi Reaches Pune’s Serum Institute to Review Oxford-AstraZeneca Vaccine Developmenton November 28, 2020 at 4:02 am
After landing at Pune airport around 4.30 pm from Hyderabad, Modi proceeded to the Serum Institute of India (SII) by helicopter.
- PM Modi Visits Vaccine Facilities Highlights: PM Modi says vaccines are not only vital to good health but also as a global goodon November 28, 2020 at 1:39 am
PM Modi is also scheduled to visit Serum Institute of India's facility to review development of the COVID-19 vaccine.
via Google News and Bing News